X0508 4 2026-02-02 0 0001802768 Royalty Pharma plc RPRX 0001814876 Coyne Terrance P. C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET NEW YORK NY 10022 0 1 0 0 EVP & CFO 1 Class A Ordinary Shares 2026-02-02 4 S 0 102581 42.0839 D 292415 I By TPC RP 2021, LLC Class A Ordinary Shares 2026-02-03 4 S 0 108759 42.8432 D 183656 I By TPC RP 2021, LLC Class A Ordinary Shares 2026-02-04 4 S 0 19076 43.2928 D 164580 I By TPC RP 2021, LLC Class A Ordinary Shares 2026-02-02 4 S 0 5843 42.0839 D 30167 I TPC RP EPA1 LLC Class A Ordinary Shares 2026-02-03 4 S 0 6195 42.8431 D 23972 I TPC RP EPA1 LLC Class A Ordinary Shares 2026-02-04 4 S 0 1087 43.2928 D 22885 I TPC RP EPA1 LLC Class A Ordinary Shares 24170 I By Spouse's IRA Class A Ordinary Shares 23270 I By IRA Class A Ordinary Shares 1500 D Class A Ordinary Shares 1450 I By Spouse All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.45 to $42.37 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $43.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.11 to $43.51 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions. /s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne 2026-02-04